Drugs / PT-523
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00088023 | Mar 2004 → Dec 2005 | neoplasm | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00112060 | Apr 2008 → Sep 2011 | non-small cell lung carcinoma | Spectrum Pharmaceuticals, Inc | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00129558 | Jul 2005 → Sep 2011 | leukemia | Spectrum Pharmaceuticals, Inc | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT-523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00112060 ↗ |
| Route | Intravenous | “short intravenous infusion” NCT00088023 ↗ |